Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma

Patients diagnosed with metastatic uveal melanoma (MUM) have a poor survival prognosis. Unfortunately for this rare disease, there is no known cure and suitable therapeutic options are limited. HDAC6 inhibitors (HDAC6i) are currently in clinical trials for other cancers and show potential beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundaramurthi, Husvinee, Giricz, Zoltán, Kennedy, Breandán N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409113/
https://www.ncbi.nlm.nih.gov/pubmed/36012642
http://dx.doi.org/10.3390/ijms23169378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409113/
https://www.ncbi.nlm.nih.gov/pubmed/36012642
http://dx.doi.org/10.3390/ijms23169378

Ejemplares similares